With over 55 million people diagnosed worldwide, Alzheimer’s disease presents a significant public health challenge, with treatment costs and caregiver burden reaching staggering figures, expected to exceed a trillion dollars soon.
Explore the latest insights into Alzheimer’s disease and drug development in Dr. Hugo Geerts’ presentation at the University of Indiana. Learn about the development of our cutting-edge Quantitative Systems Pharmacology QSP) model, integrating key disease factors to predict drug efficacy, paving the way for a new generation of disease-modifying treatments.
Deep dive into how QSP is driving the development of new Alzheimer’s treatments, in this article: